2023
LBA63 SAPPHIRE: Phase III study of sitravatinib plus nivolumab versus docetaxel in patients with previously treated advanced non-squamous non-small cell lung cancer (NSCLC)
Borghaei H, Johnson M, Garon E, He K, Planchard D, Reck M, Popat S, Herbst R, Leal T, Dumoulin D, de Marinis F, Reynolds C, Theelen W, Percent I, Calderon V, Flandin A, Shazer R, Yan X, Harrigan R, Peters S. LBA63 SAPPHIRE: Phase III study of sitravatinib plus nivolumab versus docetaxel in patients with previously treated advanced non-squamous non-small cell lung cancer (NSCLC). Annals Of Oncology 2023, 34: s1308. DOI: 10.1016/j.annonc.2023.10.064.Peer-Reviewed Original ResearchNon-squamous non-small cell lung cancerAdvanced non-squamous non-small cell lung cancerNon-small cell lung cancerCell lung cancerLung cancerSitravatinibNivolumabPatientsDocetaxelCancer
2018
A comparative clinical study of PF-06439535, a candidate bevacizumab biosimilar, and reference bevacizumab, in patients with advanced non-squamous non-small cell lung cancer.
Socinski M, Von Pawel J, Kasahara K, Bondarenko I, Syrigos K, Vladimirov V, Bryl M, Zereu M, Bair A, Hilton F, Liau K, Herbst R. A comparative clinical study of PF-06439535, a candidate bevacizumab biosimilar, and reference bevacizumab, in patients with advanced non-squamous non-small cell lung cancer. Journal Of Clinical Oncology 2018, 36: 109-109. DOI: 10.1200/jco.2018.36.15_suppl.109.Peer-Reviewed Original Research